Efgartigimod alfa: all 65 studies that test it

Page 1 of 1. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.

• Efgartigimod in Anti-NMDA Receptor Encephalitis.RecruitingNCT07822776Phase 2
• Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)Not yet recruitingNCT07806916Phase 2
• A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)Not yet recruitingNCT07760818Phase 2
• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.RecruitingNCT07596849Phase 3
• A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsNot yet recruitingNCT07583641Phase 2
• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseaseRecruitingNCT07570316Phase 3
• EFG vs IVIG in TAMGNot yet recruitingNCT07231523Phase 3
• A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)RecruitingNCT07194850Phase 2/3
• Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC EfgartigimodRecruitingNCT07072988Phase 4
• Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)Not yet recruitingNCT07011589Phase 1/2
• A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)RecruitingNCT06909214Phase 4
• Efgartigimod for the Treatment of Guillain-Barré SyndromeNot yet recruitingNCT06885762Phase 2/3
• Treatment of Myasthenia Gravis Exacerbation or Crisis With EfgartigimodRecruitingNCT06860633Phase 4
• A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)RecruitingNCT06831058Phase 2
• Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia GravisNot yet recruitingNCT06827587Not applicable
• Efgartigimod in IVIG Dependent Myasthenia Gravis PatientsRecruitingNCT06765161Phase 3
• Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic CrisisNot yet recruitingNCT06688253Phase 4
• Seronegative Myasthenia Gravis - Efgartigimod IVRecruitingNCT06587867Phase 3
• A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune ThrombocytopeniaRecruitingNCT06544499Phase 3
• Efgartigimod for Stiff Person Syndrome (ESPS)Not yet recruitingNCT06528392Phase 2
• FcRn Antagonists (Efgartigimod) for Acute NMOSD AttackNot yet recruitingNCT06497374Phase 2
• Efgartigimod for the Treatment of Acute Optic NeuritisRecruitingNCT06453694Phase 2
• A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisRecruitingNCT06392386Phase 2/3
• Perioperative Efgartigimod for Thymoma and Myasthenia GravisNot yet recruitingNCT06221501Phase 2
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyEnrolling by invitationNCT05979441Phase 3
• Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisRecruitingNCT04833894Phase 2/3
• A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's SyndromeCompletedNCT06203457Phase 2Results posted
• Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTSTerminatedNCT05918978Phase 2Results posted
• A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)CompletedNCT05817669Phase 2Results posted
• A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidTerminatedNCT05681481Phase 3Results posted
• Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSCompletedNCT05633407Phase 2Results posted
• A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidCompletedNCT05267600Phase 2/3Results posted
• An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia GravisCompletedNCT04980495Phase 3Results posted
• Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia GravisCompletedNCT04818671Phase 3Results posted
• Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia GravisCompletedNCT04735432Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaCompletedNCT04687072Phase 3Results posted
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)TerminatedNCT04598477Phase 3Results posted
• A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)CompletedNCT04598451Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).CompletedNCT04188379Phase 3Results posted
• A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.CompletedNCT03770403Phase 3Results posted
• An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessCompletedNCT03669588Phase 3Results posted
• A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessCompletedNCT02965573Phase 2Results posted
• A Study of Efgartigimod in Patients With IgG4-Related DiseaseActive, not recruitingNCT07025330Phase 2
• A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromeActive, not recruitingNCT06684847Phase 3
• A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic SclerosisActive, not recruitingNCT06655155Phase 2
• A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SCCompletedNCT06637072Phase 4
• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Phase 3
• A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.TerminatedNCT06307626Phase 3
• A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseaseTerminatedNCT06307613Phase 3
• A Study to Test How Kidney Problems Influence the Blood Concentrations of EfgartigimodCompletedNCT05927415Phase 1
• A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)TerminatedNCT05810961Phase 2
• A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)CompletedNCT05810948Phase 2
• Evaluating Efgartigimod in Patients With Guillain-Barré SyndromeWithdrawnNCT05701189Phase 2
• Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IVCompletedNCT05163834Phase 1
• A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaActive, not recruitingNCT04812925Phase 3
• A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy VolunteersCompletedNCT04564066Phase 1
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)Active, not recruitingNCT04280718Phase 2
• A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)WithdrawnNCT04274452Phase 3
• A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).CompletedNCT04225156Phase 3
• Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy SubjectsCompletedNCT04073589Phase 1
• IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy VolunteersCompletedNCT03457649Phase 1
• A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male SubjectsCompletedNCT03334084Phase 1
• A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With PemphigusCompletedNCT03334058Phase 2
• A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITPCompletedNCT03102593Phase 2

← Efgartigimod alfa overview